Cost-effectiveness of the 15-valent pneumococcal conjugate vaccine for high-risk adults in Switzerland-Reference-Cited by-同舟云学术

Cost-effectiveness of the 15-valent pneumococcal conjugate vaccine for high-risk adults in Switzerland

Published:2022-03-20 Issue:5 Volume:21 Page:711-722
ISSN:1476-0584
Container-title:Expert Review of Vaccines
language:en
Short-container-title:Expert Review of Vaccines

Author:

Deb Arijita¹,Guggisberg Patrik²,Mutschler Thomas²,Owusu-Edusei Kwame¹,Bencina Goran³^ORCID,Johnson Kelly D.¹,Ignacio Tim⁴,Mathijssen Daan A.R.⁴,Qendri Venetia⁴

Affiliation:

1. Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, USA

2. Market Access and Medical Affairs, MSD Merck Sharp & Dohme AG, Switzerland

3. Center for Observational & Real-World Evidence, Merck Sharp & Dohme, Spain

4. Modeling & Meta-Analysis (MMA) Center of Excellence (CoE), OPEN Health, The Netherlands

Funder

Merck Sharp & Dohme

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,Molecular Medicine,Immunology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14760584.2022.2046468

Reference68 articles.

1. Centers for Disease Control and Prevention. Streptococcus pneumoniae [cited 2021 Jun 30. Available from: https://www.cdc.gov/pneumococcal/clinicians/streptococcus-pneumoniae.html

2. Centers for Disease Control and Prevention. Chapter 11: penumococcal, manual for the surveillance of vaccine-preventable diseases 2020 [cited 2021 May]. Available from: https://www.cdc.gov/vaccines/pubs/surv-manual/chpt11-pneumo.html

3. Epidemiology of Invasive Streptococcus pneumoniae Infections in the United States, 1995-1998Opportunities for Prevention in the Conjugate Vaccine Era

4. Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: A systematic review of conclusions and assumptions

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lifetime Health and Economic Burden of Invasive Pneumococcal Diseases Attributable to V116 Serotypes Among Adults in the United States;Infectious Diseases and Therapy;2024-05-25

2. Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65 years-and-above in Switzerland;Vaccine;2024-05

3. Cost-Effectiveness of Pneumococcal Vaccination in Adults in Italy: Comparing New Alternatives and Exploring the Role of GMT Ratios in Informing Vaccine Effectiveness;Vaccines;2023-07-18